Citius Pharmaceuticals a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the closing of the previously announced underwritten at-the-market offering of 7,843,138 shares of its common stock and common warrants to purchase up to an aggregate of 7,843,138 shares of Common Stock.
August 13, 2018
· 4 min read